Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.
作者信息
Al-Sawaf Othman, Herling Carmen Diana, Holtick Udo, Scheid Christoph, Cramer Paula, Sasse Stephanie, von Tresckow Bastian, Tuchscherer Armin, Fischer Kirsten, Eichhorst Barbara, Hallek Michael, Frenzel Lukas P
机构信息
University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Germany.
University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Germany
出版信息
Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21.
Abstract
摘要
相似文献
1
Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.维奈克拉联合利妥昔单抗或奥妥珠单抗用于慢性淋巴细胞白血病异基因造血干细胞移植后治疗
Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21.
2
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.维奈托克联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病：一项1b期研究
Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.
3
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.维奈托克与奥妥珠单抗治疗慢性淋巴细胞白血病
Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21.
4
Pairing obinutuzumab with venetoclax in relapsed CLL.在复发的慢性淋巴细胞白血病中，将奥妥珠单抗与维奈克拉联合使用。
Leuk Lymphoma. 2024 May;65(5):543-545. doi: 10.1080/10428194.2024.2323682. Epub 2024 Mar 18.
5
Venetoclax plus rituximab for chronic lymphocytic leukaemia.维奈托克联合利妥昔单抗治疗慢性淋巴细胞白血病
Lancet Oncol. 2018 May;19(5):e233. doi: 10.1016/S1470-2045(18)30259-6. Epub 2018 Mar 29.
6
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.维奈托克联合奥滨尤妥珠单抗治疗复杂核型慢性淋巴细胞白血病患者疗效显著。
Blood. 2020 Mar 12;135(11):866-870. doi: 10.1182/blood.2019003451.
7
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.维奈托克联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病。
N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.
8
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Venetoclax-Obinutuzumab 治疗初治及复发/难治性慢性淋巴细胞白血病的 1b 期临床研究。
Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12.
9
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.苯达莫司汀后继奥滨尤妥珠单抗和维奈克拉治疗慢性淋巴细胞白血病（CLL2-BAG）：多中心、开放标签、2 期试验的主要终点分析。
Lancet Oncol. 2018 Sep;19(9):1215-1228. doi: 10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13.
10
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.维奈托克联合利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病的持续时间：MURANO Ⅲ期研究的治疗后随访结果，可消除微小残留病灶并延长生存。
J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3.
引用本文的文献
1
Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era.现代时期慢性淋巴细胞白血病异基因造血移植的结果
Intern Med J. 2025 Jul;55(7):1105-1113. doi: 10.1111/imj.70050. Epub 2025 May 3.
2
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation.维奈托克治疗异基因造血干细胞移植后复发的慢性淋巴细胞白血病患者。
Br J Haematol. 2025 Mar;206(3):924-929. doi: 10.1111/bjh.19976. Epub 2025 Jan 7.
3
The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review.异基因造血细胞移植在慢性淋巴细胞白血病中的作用：综述
Front Oncol. 2023 Jan 18;12:1105779. doi: 10.3389/fonc.2022.1105779. eCollection 2022.
本文引用的文献
1
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.在通路抑制剂时代的高危慢性淋巴细胞白血病：整合分子和细胞疗法。
Blood. 2018 Aug 30;132(9):892-902. doi: 10.1182/blood-2018-01-826008. Epub 2018 Jul 11.
2
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Venetoclax 单药治疗复发/难治性慢性淋巴细胞白血病患者的全面安全性分析。
Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. doi: 10.1158/1078-0432.CCR-17-3761. Epub 2018 Jun 12.
3
How and when I do allogeneic transplant in CLL.在 CLL 中，我何时以及如何进行异基因移植。
Blood. 2018 Jul 5;132(1):31-39. doi: 10.1182/blood-2018-01-785998. Epub 2018 May 11.
4
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.维奈托克治疗伴有 17p 缺失的慢性淋巴细胞白血病患者：来自 II 期关键性试验全人群的结果。
J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.
5
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.维奈托克联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病。
N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.
6
Chronic lymphocytic leukaemia.慢性淋巴细胞白血病。
Lancet. 2018 Apr 14;391(10129):1524-1537. doi: 10.1016/S0140-6736(18)30422-7. Epub 2018 Feb 21.
7
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.伊布替尼用于既往治疗失败后的慢性移植物抗宿主病。
Blood. 2017 Nov 23;130(21):2243-2250. doi: 10.1182/blood-2017-07-793786. Epub 2017 Sep 18.
8
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.高危慢性淋巴细胞白血病的异基因造血细胞移植：GCLLSG CLL3X试验的10年随访
Blood. 2017 Sep 21;130(12):1477-1480. doi: 10.1182/blood-2017-04-775841. Epub 2017 Jul 17.
9
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.维奈托克与奥妥珠单抗治疗慢性淋巴细胞白血病
Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21.
10
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.维奈托克联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病：一项1b期研究
Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.
Zotero 插件